Investor Presentaiton
Cell therapy: CAR-T is by far the Most Popular Modality Currently Focused on Hematological
Malignancies, Solid Tumor Targets and Autoimmune Disease Targets are also being Pursued
Cell therapy pipeline breakdown by cell type and phase
BLA/ approval
1,200
Ph3
Ph2/3
1,000
Ph2
Ph1/2
800
Ph1
Modified T cells
Unmodified T cells
NK cells
600
IND
400
PCC
200
0
Source: Pharm Cube NextPharma database; Date cutoff 05/2023
CAR-T
TCR-T
CAR-VOT
CAR-Treg
CAR-CIK
TCR-YOT
TIL
Treg
убт
CIK
Others
CAR-NK
NK
Macrophages
TCR-NK
CAR-M
Macrophage
Dendritic cells
Pipeline breakdown by target
0%
2% 4% 6%
8%
CD19
BCMA
CD22
CD20
CD33
CD123
DC
Hematological
malignancies
CD7
CLL-1
CD38
MSLN
HER2
GPC3
EGFR
NY-ESO-1
CLDN18.2
CD70
Solid tumour
B7-H3
EBV
KARS
PSMA
3 药明康德
Wuxi AppTecView entire presentation